Search Site

SIB’s 2024 profit $272m

The profit surpassed AED 1 billion for the first time in bank's history.

AD Ports to invest in Kazakh port

Under the deal, AD Ports Group owns 51% stake.

PIF acquires stake in Saudi Re

The acquisition was made by way of a capital increase.

ADNOC Gas awards contracts

The $2.1bn contracts are aimed at enhancing LNG supply infrastructure.

ADNOC L&S buys stake in Navig8

The company will acquire the remaining stake in mid-2027.

Glaxo buys Bellus for US$2bn

A Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026. (AFP)
  • GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, the British drugmaker said in a statement.
  • Chronic cough is defined as a persistent cough that lasts more than eight weeks and affects an estimated 28 million people worldwide.

LONDON, UK – British drugmaker GlaxoSmithKline on Tuesday announced the purchase of Canadian chronic cough treatment specialist Bellus for US$2 billion.

It comes after GSK, led by chief executive Emma Walmsley, demerged its consumer healthcare unit Haleon last year, leaving the group to focus on drugs.

GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, it said in a statement.

Chronic cough, defined as a persistent cough that lasts more than eight weeks, affects an estimated 28 million people worldwide.

While there are no approved medicines in the European Union or United States, a Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026.

“Patients suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues,” GSK’s chief commercial officer Luke Miels said in the statement.

“Camlipixant… has the potential to be a best-in-class treatment with significant sales potential,” he added.